iA Global Asset Management Inc. boosted its stake in Insmed, Inc. (NASDAQ:INSM – Free Report) by 15,973.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,682 shares of the biopharmaceutical company’s stock after acquiring an additional 26,516 shares during the period. iA Global Asset Management Inc.’s holdings in Insmed were worth $4,644,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC raised its holdings in Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. CoreCap Advisors LLC acquired a new stake in Insmed in the fourth quarter valued at $27,000. SBI Securities Co. Ltd. raised its holdings in Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 166 shares in the last quarter. GraniteShares Advisors LLC acquired a new stake in Insmed in the fourth quarter valued at $30,000. Finally, Whittier Trust Co. of Nevada Inc. raised its holdings in Insmed by 169.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 151 shares in the last quarter.
Insmed Price Performance
Shares of NASDAQ:INSM opened at $109.14 on Monday. The stock has a market capitalization of $23.66 billion, a price-to-earnings ratio of -18.98 and a beta of 0.89. Insmed, Inc. has a 1-year low of $64.85 and a 1-year high of $212.75. The company’s fifty day moving average is $141.33 and its two-hundred day moving average is $163.25. The company has a debt-to-equity ratio of 0.80, a quick ratio of 4.10 and a current ratio of 4.47.
Insiders Place Their Bets
In related news, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $150.98, for a total value of $2,964,945.24. Following the sale, the insider owned 51,871 shares of the company’s stock, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $143.97, for a total transaction of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,361,604.45. This trade represents a 3.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 161,193 shares of company stock valued at $25,462,012. Company insiders own 2.10% of the company’s stock.
Analyst Ratings Changes
Several analysts recently issued reports on the stock. Wells Fargo & Company cut their price target on shares of Insmed from $177.00 to $160.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Roth Mkm reaffirmed a “buy” rating and issued a $212.00 price target on shares of Insmed in a report on Friday, April 17th. Barclays upped their price target on shares of Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a report on Wednesday, April 1st. Truist Financial cut their price target on shares of Insmed from $205.00 to $185.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Bank of America increased their target price on shares of Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $210.95.
Read Our Latest Report on INSM
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Featured Stories
- Five stocks we like better than Insmed
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
